TrialAdvances in therapy2026

Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.

Daniel J Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.